Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Solaro

Showing results (121-130 of 140) with videos related to

Pageof 14
Sort By:
Computer Methods and Programs in Biomedicine|November 8, 2021
Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]Edward De Brouwer, Thijs Becker, Yves Moreau, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 29, 2025
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Computer Methods and Programs in Biomedicine|June 19, 2021
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progressionEdward De Brouwer, Thijs Becker, Yves Moreau, et al.
Multiple Sclerosis and Related Disorders|January 10, 2019
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort studyAi-Lan Nguyen, Eva Kubala Havrdova, Dana Horakova, et al.
Computer Methods and Programs in Biomedicine|February 18, 2025
Explainable time-to-progression predictions in multiple sclerosisRobbe D'hondt, Klest Dedja, Sofie Aerts, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 15, 2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisTomas Kalincik, Eva Kubala Havrdova, Dana Horakova, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2019
Risk of secondary progressive multiple sclerosis: A longitudinal studyAdam Fambiatos, Vilija Jokubaitis, Dana Horakova, et al.
European Journal of Neurology|May 18, 2022
Confirmed disability progression as a marker of permanent disability in multiple sclerosisSifat Sharmin, Francesca Bovis, Charles Malpas, et al.
PLOS Digital Health|July 25, 2024
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center studyEdward De Brouwer, Thijs Becker, Lorin Werthen-Brabants, et al.
Pageof 14

Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
Computer Methods and Programs in Biomedicine|November 8, 2021
Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]Edward De Brouwer, Thijs Becker, Yves Moreau, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 29, 2025
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Computer Methods and Programs in Biomedicine|June 19, 2021
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progressionEdward De Brouwer, Thijs Becker, Yves Moreau, et al.
Multiple Sclerosis and Related Disorders|January 10, 2019
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort studyAi-Lan Nguyen, Eva Kubala Havrdova, Dana Horakova, et al.
Computer Methods and Programs in Biomedicine|February 18, 2025
Explainable time-to-progression predictions in multiple sclerosisRobbe D'hondt, Klest Dedja, Sofie Aerts, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 15, 2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisTomas Kalincik, Eva Kubala Havrdova, Dana Horakova, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2019
Risk of secondary progressive multiple sclerosis: A longitudinal studyAdam Fambiatos, Vilija Jokubaitis, Dana Horakova, et al.
European Journal of Neurology|May 18, 2022
Confirmed disability progression as a marker of permanent disability in multiple sclerosisSifat Sharmin, Francesca Bovis, Charles Malpas, et al.
PLOS Digital Health|July 25, 2024
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center studyEdward De Brouwer, Thijs Becker, Lorin Werthen-Brabants, et al.
Pageof 14